Darunavir
Darunavir can induce a variety of delayed skin eruptions from mild MPE
in most cases, to severe bullous cutaneous reactions in HIV infected
patients (45,
61). A phase III randomized clinical
trial performed in 604 patients treated with darunavir/r or LPV/r showed
that the percentage of patients experiencing rash was higher in those
receiving darunavir/r compared with others (16% vs 7%). Two patients
receiving darunavir/r required treatment cessation due to a severe rash
(45). Darunavir contains a sulfonamide
moiety and should be used with caution in patients with a known
sulfonamide allergy (62). Desensitization
was reported to be successful in patients with non-immediate
hypersensitivity reactions (NIHRs) to darunavir
(63,64).